GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01950637

Enrollment

4000

Registered

2013-09-25

Start date

2012-01-31

Completion date

2013-01-31

Last updated

2017-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This study is conducted Asia, Europe and North America. The aim of this study is to describe insulin therapy adherence and the burden of non-adherence on patient functioning, well-being and diabetes management.

Interventions

BEHAVIORALNo treatment given

Completion of 90-item online questionnaire.

BEHAVIORALsurvey

Completion of 58-item online questionnarie.

Study design

Observational model

ECOLOGIC_OR_COMMUNITY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* PATIENTS WITH T2DM: * Diagnosed with type 2 diabetes by a healthcare professional * Currently being treated with insulin medication, excluding premix insulin treatment * Age at least 40 years * Diagnosed as having type 2 diabetes over the age of 40 * HCPs: * Primary care physician, diabetes specialist (diabetologist/endocrinologist) or diabetes specialist nurse/diabetes nurse educator * Have a minimum of 2 years experience within current speciality * See a minimum of 20 type 2 diabetes patients per month (40 for diabetes specialists), of which at least 10 per month must be on modern (analogue) inulins

Design outcomes

Primary

Measure	Time frame
Basal insulin dosing irregularities: frequency of missed doses, mistimed doses, or reduced doses (patient questionnaire)	In the past 30 days prior to the day when responding to the online questionnaire
Level of patient dosing irregularity: missed, mistimed and reduced dose (HCP questionnaire)	Day 1 (when responding to the online questionnaire)

Secondary

Measure	Time frame
Incidence of intentional dosing irregularities and reasons for this behaviour	Day 1 (when responding to the online questionnaire)
Impact of dosing irregularity on functional well-being	Day 1 (when responding to the online questionnaire)
Frequency of self-treated hypoglycaemia	In the past 30 days prior to the day when responding to the online questionnaire

Countries

Canada, Denmark, Germany, Japan, United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026